2020 Articles

Volume 2 Issue 1

Psilocybin Assisted Psychotherapy Protocol

Gershom Hernandez, M.D.

Volume 2 Issue 1

Abstract: Psychotherapy protocols have been established for psychedelic-assisted therapy. No such protocol for psilocybin assisted psychotherapy is currently available. This paper aims to produce a protocol for psilocybin assisted psychotherapy for treatment-resistant depression that is in line with current methods and protocols, and one that includes an evidence-based treatment framework.

Methods: Pub med search for evidence-based therapies for depression and review of currently existing protocols for psychedelic-assisted therapies.

Results: A potential protocol for psilocybin assisted therapy to serve as a framework for future studies and to further discussion. More research is required to determine the most efficacious forms of therapy in combination with the potential of psychedelics.

Integrating Psychedelic Use: A Cautionary Note for Licensed Healthcare Providers

Rose Jade, LCSW

Volume 2 Issue 1

Viewpoint

Positive Response to Ketamine Administration in Treatment Resistant Psychosis: A Case Report

Joseph Pullara, M.D.

Volume 2 Issue 1

Abstract:

The pathophysiology underlying the schizophrenia spectrum of disorders has been a topic of research for decades. Ketamine has been used as a model for psychosis for over 20 years. Treatment of refractory cases of schizophrenia and similar disorders remains a challenging aspect of psychiatry. This case report describes the case of a 45-year-old woman with treatment-refractory schizoaffective disorder who was transitioned off of clozapine due to neutropenia. This resulted in psychotic destabilization and a complicated clinical course, ultimately resulting in a re-trial of clozapine after the failure of alternative psychotropic treatment. During this trial, an MRI brain was obtained, which required a sedating dose of intravenous ketamine due to patient agitation. After just a single dose of ketamine, resolution of behavioral activation and agitation was noted for a short period, something which had not been seen in over a month of hospitalization.

Selective Use of Ketamine in Patients with Psychotic Disorders

Tyler Kjorvestad, M.D.

Volume 2 Issue 1

Editorial

A Review of the Psychotherapeutic Effects of Ayahuasca

Adam Bertroche, D.O.

Volume 2 Issue 1

Abstract:

Objective: This paper aims to outline the background, pharmacology, subjective effects, and tolerability of the South American hallucinogenic tea, ayahuasca.

Methods: Literature Review

Discussion: Ayahuasca is a South American hallucinogenic tea that has been used in shamanistic practices for centuries and has become popularized globally through use by Brazilian churches and has potential implications for the treatment of psychiatric conditions due to its serotonergic activity. It relies on monoamine oxidase inhibition to prevent degradation of its psychoactive ingredient, DMT, allowing it to be absorbed into the systemic circulation and act centrally. Subjective effects acutely include perceptual, cognitive, affective, and somatic changes and is generally well tolerated with mild increased in cardiovascular parameters, possible gastrointestinal symptoms such as vomiting, and rarely prolonged psychosis

  • Facebook Social Icon
  • Instagram

©2019 by The Journal of Psychedelic Psychiatry. Proudly created with Wix.com